Related Experiment Video
Updated: Aug 13, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Neoadjuvant and adjuvant therapy for rectal cancer
J Pablo Arnoletti1, Kirby I Bland
1Section of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, 1922 7th Avenue South, KB321, Birmingham, AL 35294, USA.
Surgical Oncology Clinics of North America
|January 4, 2006
Summary
Adjuvant therapy, particularly preoperative combined modality therapy, effectively reduces local recurrence and improves outcomes for rectal cancer. Further research is needed for biomarkers to personalize treatment and improve survival rates.
Area of Science:
- Colorectal surgery
- Oncology
- Gastroenterology
Background:
- Locally advanced rectal adenocarcinomas require effective treatment strategies.
- Current evidence supports adjuvant and preoperative therapies for improved patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of adjuvant and preoperative combined modality therapy for rectal cancer.
- To identify the role of radical surgery and the need for predictive biomarkers.
Main Methods:
- Review of randomized clinical trials on adjuvant and preoperative therapies for rectal cancer.
- Analysis of surgical approaches including Total Mesorectal Excision (TME).
Main Results:
- Preoperative combined modality therapy significantly decreases local recurrence rates.
- Improved sphincter preservation and likely enhanced overall survival observed.
- Radical surgery with TME remains the standard of care.
Conclusions:
- Adjuvant and preoperative therapies are crucial for managing advanced rectal cancer.
- Development of surrogate biomarkers is essential for treatment optimization.
- Ongoing advancements in therapy aim to further improve local control and survival.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...